Acurx shares surge 30.22% intraday as Q3 2025 financials show improved cash and reduced liabilities, and clinical progress in antibiotic development for severe bacterial infections.

Acurx surged 30.22% intraday, driven by improved Q3 2025 financials showing increased cash to $5.91 million and reduced liabilities to $2.47 million, alongside ongoing clinical progress in developing novel antibiotics for severe bacterial infections. The company focuses on antibiotic development targeting serious infections, with its clinical-stage pipeline attracting market attention.